优思弗治疗胆汁淤积性肝病64例临床观察

Clinical observation on 64 cases of cholestasis hepatopathy treated with Ursofalk （UDCA）

目的观察优思弗对胆汁淤积性肝病的疗效。方法128例胆汁淤积性肝病病人随机分为治疗组和对照组，每组各64例，对照组给予甘利欣及常规护肝治疗，治疗组在与对照组相同治疗的基础上再给予优思弗250mg／次，3次，d，po，疗程均为8wk。结果治疗后两组在症状恢复方面比较：纳差、乏力症状有明显改善，但差异无显著性（P〉0．05）；而皮肤瘙痒差异有显著性（P〈0．05）。体征复常方面比较：肝、脾肿大差异无显著性（P〉0．05）；而胆囊壁增厚、水肿差异有显著性（P〈0．05）。治疗组治疗后肝功能指标下降幅度均明显优于对照组，差异有显著性，其中总胆红素（TBi1）、直接胆红素（DBi1）、胆汁酸（TB）与对照组比较，P〈0．01；丙氨酸氨基转移酶（ALT）、碱性磷酸酶（ALP）、γ-谷氨酰转移酶（T-GT）与对照组比较P〈0．05。根据疗效判定标准，总有效率为93．75％，与对照组比较P〈0．01。结论优思弗治疗胆汁淤积性肝病疗效显著，可作为胆汁淤积性肝病的首选药物。

Objective To observe the efficacy of Ursofalk （UDCA） in treatment of cholestasis hepatopathy. Methods 128 patients with cholestasis hepatopathy were randomly divided into therapeutic and control group, there were 64 cases in each group. The control group was given Glycyrrhizinate and routine liver protective treatment; the treatment group was added with oral capsule of UDCA, 250mg thrice daily. The courses of each group treatment were 8 weeks, Results The clinical symptoms of low appetite and fatigue were improved without significant difference between two groups （P〉0.05）, whereas skin itchings were significant different （P〈0.05）. The signs of hepatolienomegaly hepatomegaly and spleen enlargement recovered without significance （P〉0.05）, while cholecystic wall thickening and edema showed significantly recovered （P〈0.05）. The levels of liver function in therapeutic group were lower than those in control group, inciuding TBil, DBil, TB （P〈0.01）, and ALT, ALP, γ-GT （P〈0.05）. The total effective rate was 93.75%. Conclusion UDCA has marked effectiveness in treatment of cholestasis hepatopathy, and may become the first-chose drug.